secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2025-06-27T23:59:59+00:00
Accession:  0001193125-25-150301
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics raises $5M upfront (up to $15M with warrant exercise) in equity offering
--------------------------------------------------------------------------------

- Upfront gross proceeds of $5.0M from sale of 423,372 shares (or pre-funded warrants) at $11.81 per share+private warrant.
- Additional up to $9.8M if private warrants (846,744 shares at $11.56) exercised fully; warrants expire 24 months after resale registration effective.
- Net proceeds ~$4.3M after placement agent fees (7% cash fee plus 6.5% on future warrant exercises).
- Proceeds to be used for working capital and potential clinical development/manufacturing of LYR-210 for chronic rhinosinusitis.
- Company previously terminated ~87 employees after failed ENLIGHTEN 1 Phase 3 trial and faces going concern risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000119312525150301/0001193125-25-150301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000119312525150301/d75821d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-150301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer